Skip to content

The implication of secondary transurethral resection in non-muscle invasive bladder cancer: multicenter, prospective, randomized, controlled clinical trial

The implication of secondary transurethral resection in non-muscle invasive bladder cancer: multicenter, prospective, randomized, controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007461
Enrollment
Unknown
Registered
2015-11-23
Start date
1990-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Interventions

Treatment group:secondary transurethral resection
Control group:transurethral resection for one time

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years old, Male or female; 2. All cases were pathologically diagnosed with non-muscle-invasive urothelial carcinoma and without other components (eg: adenocarcinoma, squamous cell carcinoma, sarcoma); 3. All patients undergo standard TURBT by senior physicians and receive routine intravesical instillation; (pirarubicin or other infusion drugs); 4. Patient is able to understand the trail, sign the informed consent and are willing to get regular follow-up.

Exclusion criteria

Exclusion criteria: 1. muscle invasive and lymph node or distant metastasis; 2. tumor grade and stage can not be accurately assessed; 3. visible tumor were not completely removed at the first TURBT due to tumor location, obturator nerve reflex and other reasons; 4. the confirmed or suspected bladder perforation; 5. the clinical data is incomplete; 6. combined with other serious diseases and life expectancy <2 years; 7. pregnancy or lactating women; 8. can not understand the content of the trail and sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Recurrence rate;

Secondary

MeasureTime frame
Progression rate;Survival rate;

Countries

China

Contacts

Public ContactChaozhao Liang
yc8000@163.com+86 551 62923440

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026